Per Brandtzaeg, MS, DDS, PhD

Centre for Immune Regulation, University of Oslo and Oslo Univerity Hospital
LIIPAT, Institute of Pathology
Rikshospitalet University Hospital
Oslo Norway N-0027

Biographical Sketch: Brandtzaeg trained in microbiology and immunology at the Medical Center of the University of Alabama at Birmingham before earning his Ph.D. in immunology from the University of Oslo. Until recently he headed the Faculty Division of Rikshospitalet University Hospital, and he is the founder of its Laboratory for Immunohistochemistry and Immunopathology. Brandtzaeg’s research examines the biology and pathology of the mucosal immune system, including the study of mucosal diseases associated with chronic inflammation, allergy, immunodeficiency, and malignant and reactive disorders of mucosal and peripheral lymphoid tissue. Brandtzaeg has been Norway’s most cited researcher over the past two decades and was the first European president of the international Society for Mucosal Immunology.

Any personal financial relationships? No

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 02/13/2015 by Per Brandtzaeg

Papers:
History of Mucosal Immunology: Secretory Immunity and Oral Tolerace

	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".